|
FOENIX-CCA2: A phase II, open-label, multicenter study of futibatinib in patients (pts) with intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 gene fusions or other rearrangements. |
|
|
Consulting or Advisory Role - Agios; Alentis Therapeutics; AstraZeneca; Debiopharm Group; H3 Biomedicine; Klus Pharma; QED Therapeutics; Taiho Pharmaceutical |
Research Funding - Taiho Pharmaceutical |
Travel, Accommodations, Expenses - Debiopharm Group; Taiho Pharmaceutical |
|
|
Employment - MD Anderson Cancer Center |
Honoraria - Dialectica; Sumitomo Group |
Consulting or Advisory Role - Aduro Biotech; Clearlight Diagnostics; DarwinHealth; Debiopharm Group; eFFECTOR Therapeutics; Genentech; IBM; IBM; Immunomedics; Inflection Biosciences; Mersana; Origimed; PACT Pharma; Pieris Pharmaceuticals; Roche; Samsung Bioepis; Seagen; Silverback Therapeutics; Spectrum Pharmaceuticals; Xencor |
Speakers' Bureau - Chugai Pharma |
Research Funding - Abbvie (Inst); Aileron Therapeutics (Inst); AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (I); Calithera Biosciences (Inst); Curis (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Debiopharm Group (Inst); eFFECTOR Therapeutics (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Guardant Health (Inst); Jounce Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); PUMA Biotechnology (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst); Zymeworks (Inst) |
Travel, Accommodations, Expenses - Beth Israel Deaconess Medical Center; Seagen; Taiho Pharmaceutical |
|
|
|
Consulting or Advisory Role - Amgen; AstraZeneca/MedImmune (Inst); Debiopharm Group (Inst); Gritstone Bio; Incyte (Inst); Lilly (Inst); Spectrum Pharmaceuticals (Inst) |
Travel, Accommodations, Expenses - Amgen; AstraZeneca/MedImmune; Incyte; Lilly; Roche; SERVIER |
Other Relationship - Abbvie; Agios; Amgen; argenx; Arno Therapeutics; Astex Pharmaceuticals; AstraZeneca; AVEO; Bayer; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Chugai Pharma; Clovis Oncology; Daiichi Sankyo; Debiopharm Group; Eisai; Exelixis; FORMA Therapeutics; GamaMabs Pharma; Genentech; GlaxoSmithKline; H3 Biomedicine; Innate Pharma; Janssen-Cilag; Kyowa Hakko Kirin; Lilly; Loxo; Lytix Biopharma; MedImmune; Menarini; Merck Sharp & Dohme; Merrimack; Merus; Millenium Pharamceuticals; Nanobiotix; Nektar; Novartis; Octimet; Oncoethix; Onyx; Orion; Oryzon Genomics; Pfizer; Pierre Fabre; Roche; Roche/Genentech; Sanofi/Aventis; SERVIER; Taiho Pharmaceutical; Tesaro; Xencor |
|
|
|
Consulting or Advisory Role - Agios; AstraZeneca; Debiopharm Group; Delcath Systems; Genoscience Pharma; Imaging Equipment Limited; Incyte; Ipsen; Keocyt; Merck; Mundipharma; Novartis; Nucana; PCI Biotech; Pfizer; Pieris Pharmaceuticals; QED Therapeutics; SERVIER; Wren Laboratories |
Speakers' Bureau - Imaging Equipment Limited; Ipsen; Novartis; Nucana |
Research Funding - Novartis (Inst) |
Travel, Accommodations, Expenses - Celgene; Nucana; Pfizer |
|
|
Honoraria - Eisai; Merck Sharp & Dohme; Novartis; Taiho Pharmaceutical; Teijin Pharma; Yakult Honsha |
Consulting or Advisory Role - Abbvie; Novartis; Taiho Pharmaceutical; Yakult Honsha |
Research Funding - AstraZeneca (Inst); Eisai (Inst); J-Pharma (Inst); Merck (Inst); ONO PHARMACEUTICAL (Inst); Taiho Pharmaceutical (Inst); Yakult Honsha (Inst) |
|
|
Research Funding - Bristol-Myers Squibb; Celgene; H3 Biomedicine; Lilly; Sirtex Medical; Syndax; Taiho Pharmaceutical |
|
|
Stock and Other Ownership Interests - Guardant Health; InVitae; Jounce Therapeutics |
Consulting or Advisory Role - Aduro Biotech; Bayer; Bristol-Myers Squibb; Eisai; Exelixis/Ipsen; Kaleido Biosciences; Merck |
|
Expert Testimony - Genentech |
|
|
Honoraria - Abbvie; Astellas Pharma; AstraZeneca; Bayer Yakuhin; Chugai Pharma; Daiichi Sankyo; EA Pharma; Eisai; Fujifilm; J-Pharma; Kyowa Hakko Kirin; Lilly Japan; Merck Serono; Mochida Pharmaceutical Co. Ltd.; MSD; Nihon Servier; Nippon Kayaku; Novartis; Ono Pharmaceutical; Pfizer; Sanofi; Sawai Pharmaceutical Co; Shionogi; Shire; Sumitomo Dainippon; Taiho Pharmaceutical; Takeda; Teijin Pharma; Yakult Honsha |
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer Yakuhin; Chugai Pharma; Eisai; Fujifilm; J-Pharma; Lilly Japan; MSD; Novartis; Ono Pharmaceutical; Otsuka; Shire; Sumitomo Dainippon; Taiho Pharmaceutical; Takara Bio; Yakult Honsha |
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); J-Pharma (Inst); Kyowa Hakko Kirin (Inst); Lilly Japan (Inst); Mochida Pharmaceutical Co. Ltd. (Inst); MSD (Inst); NanoCarrier (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Sanofi (Inst); Sumitomo Dainippon (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Yakult Honsha (Inst) |
|
|
Employment - Taiho Pharmaceutical |
|
|
No Relationships to Disclose |
|
|
Employment - Lilly; Taiho Pharmaceutical |
Stock and Other Ownership Interests - Lilly |
|
|
Honoraria - Merck Serono; SERVIER |
Consulting or Advisory Role - AstraZeneca; Basilea; Bayer; Incyte; Merck Serono; Merck Serono; Roche; SERVIER |
Speakers' Bureau - Amgen; Bristol-Myers Squibb; Celgene |
|
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Bristol-Myers Squibb/Medarex; Merck Serono; MSD Oncology; SERVIER |